Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
University of Alberta
$585,228.00
Optimizing polar, small inhibitors of a viral cysteine protease to identify a lead for an oral COVID-19 treatment
EF 2020-21
Résumé
The COVID-19 pandemic has caused incredible social, personal and economic upheaval and as of early May 2020 killed 275 000 people world-wide and, tragically, is projected to kill millions more. COVID-19 is caused by the SARS-CoV2 (SARS2) virus, which is a coronavirus closely related to SARS. These viruses infect cells and using the host's enzymes and virally encoded proteins create copies of themselves. These viral proteins are different than the host
ones and are key targets to stop the viral replication. One such protein for SARS2, nicknamed 3CLP, is key to liberating the viral proteins in order to enable viral replication. Last month compounds we tested strongly inhibited the SARS2 3CLP and were able to inhibit SARS2 replication in a cell-based assay. This proposal is to design and make modifications of those compounds to better inhibit SARS2 and also optimize drug-like properties to discover a Lead compound for the ultimate development of an oral drug to treat COVID-19.
Programme
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429698
Name
Lemieux Joanne M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
COVID-19 Rapid Research - Therapeutics
Projecttitle
Optimizing polar, small inhibitors of a viral cysteine protease to identify a lead for an oral COVID-19 treatment
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$585,228
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Keyworddelim
Antiviral Drugs; Co-Crystallization; Coronavirus; Covid-19; Cysteine Protease Inhibitor; Lead Identification; Molecular Modelling; Sars-Cov-2; Small Molecule Drug Discovery
Abstract
The COVID-19 pandemic has caused incredible social, personal and economic upheaval and as of early May 2020 killed 275 000 people world-wide and, tragically, is projected to kill millions more. COVID-19 is caused by the SARS-CoV2 (SARS2) virus, which is a coronavirus closely related to SARS. These viruses infect cells and using the host's enzymes and virally encoded proteins create copies of themselves. These viral proteins are different than the host
ones and are key targets to stop the viral replication. One such protein for SARS2, nicknamed 3CLP, is key to liberating the viral proteins in order to enable viral replication. Last month compounds we tested strongly inhibited the SARS2 3CLP and were able to inhibit SARS2 replication in a cell-based assay. This proposal is to design and make modifications of those compounds to better inhibit SARS2 and also optimize drug-like properties to discover a Lead compound for the ultimate development of an oral drug to treat COVID-19.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lemieux, Joanne M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $585,228~ $0~
